Previous Pause Next
Home >> News Center >> Products & Services >> Novel Products >>
Hyglos Introduces EndoLISA®, The World’s First ELISA-Based Endotoxin Detection Method PDF Print E-mail
User Rating :  / 0
Monday, 17 October 2011 18:11

Hyglos today has the pleasure to present EndoLISA®, the world’s first commercially available ELISA-based endotoxin detection method.

EndoLISA® is the result of several years of research and test development aimed at establishing a better performing alternative to LAL. Hyglos has developed and optimized a lipopolysaccharide (LPS) specific phage- derived protein as well as optimal sample conditions, in order to specifically cover the entire substance group of LPS (endotoxin).

The phage protein is pre-coated to the wells in a microtiter plate and as the sample is added to the well, the endotoxin (LPS) in the sample is bound to the phage protein. Any sample matrix with potentially interfering components is then completely removed by a washing step. Therefore, the subsequent detection by recombinant Factor C and a fluorescence substrate is thus left unaffected by inhibitors, facilitating a reliable quantification of endotoxin in the sample.

EndoLISA® at a glance:

•Overcomes limitations of existing methods, such as the need for substantial dilution
•Reduced matrix effects due to integrated washing step
•Robust assay with excellent reproducibility
•Validation studies have shown that EndoLISA® has a much higher tolerance to varying salt conditions as well as chaotropic agents and organic solvents than LAL
About Endotoxins:

Lipopolysaccharides (LPS), or endotoxins, are biologically active components (toxins) of the outer cell membrane of all Gram-negative bacteria. Presence of endotoxins in the blood stream causes a triggering of the signaling cascade and can lead to endotoxic shock. In production of pharmaceuticals, it is necessary to control endotoxin, as small amounts will cause illness in humans. About Hyglos GmbH: Hyglos is an international biotech company based in Germany. Its core competency to exploit the principles of bacteriophage biology and the expert use of the proprietary phage-ligand technology for research, diagnostic and antimicrobial applications. Press contact: Hyglos GmbH

Karolina Heed ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it )
Am Neuland 3
D-82347 Bernried am Starnberger See, Germany
Tel. +49 (0) 8158-9060-0; Fax +49 (0) 8158-9060-210


Source: Hyglos GmbH


Add comment  |   Add to my library  |  Forward this article

login to leave comment